Stada Arzneimittel confirmed a third potential bidder has expressed interest in the German generic drug maker, lifting shares to an all-time high. Stada Arzneimittel confirmed a third potential ...

STADA Arzneimittel Aktiengesellschaft (FRA:SAZ) generated a below-average return on equity of 9.54% in the past 12 months, while its industry returned 12.18%. An investor may attribute an inferior ...

As Stada Arzneimittel’s private equity owners continue to weigh their options around a potential sale or public offering, the German drugmaker gave a good indication Wednesday of exactly what it ...

(Bloomberg) -- Stada Arzneimittel AG’s private equity owners are pushing back a planned initial public offering of the German drugmaker until September, people with knowledge of the matter said.

German drugmaker Stada Arzneimittel AG said Monday it would support a sweetened joint takeover offer by private-equity firms Bain Capital LLC and Cinven Group Ltd. worth €4.11 billion ($4.35 ...

Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by ...

Press release 2018-07-12 Xbrane Biopharma AB ("Xbrane") and STADA Arzneimittel AG ("STADA") have entered into a co-development agreement for Xlucane, a Lucentis® (ranibizumab) biosimilar. About ...

Stada Arzneimittel AG is sounding out investors for its initial public offering that could potentially raise around €1.5 billion ($1.6 billion) of fresh capital for the consumer health-focused ...

FRANKFURT—Germany is gearing up for a rare proxy fight between activist investors and a company’s incumbent management with pressure mounting on the board of generic drugmaker Stada ...

Stada Arzneimittel AG’s takeover by two private-equity suitors risks falling apart a second time in as many months unless investors shake off their complacency and tender more shares ahead of a ...

German pharmaceutical company Stada Arzneimittel has opened a new production facility in Turda, Romania. Initially announced in late 2022, Stada’s new hub represents an investment of around $75m ...

LONDON (MarketWatch) -- German generics drugmaker Stada Arzneimittel AG rose 3.1 percent as it said net income in 2004 rose 10.5 percent to 48.5 million euros, on a good fourth quarter and cost ...